Illumina Stock May Benefit From New Agreement to Acquire SomaLogic

Illumina (ILMN) has agreed to acquire SomaLogic from Standard BioTools (LAB) for $350 million in cash, plus up to $75 million in performance-based payments, with the deal expected to close in H1 2026. This strategic acquisition is set to significantly enhance Illumina's multiomics strategy and expand its footprint in the rapidly growing proteomics market, projected to reach $41.65 billion by 2025. The integration of SomaLogic's data-driven proteomics technology with Illumina's NGS ecosystem is anticipated to accelerate proteomic research and add a high-margin consumable revenue stream, with the acquired business expected to achieve non-GAAP profitability by 2027. Following the announcement, ILMN shares jumped 2.9%, reflecting positive market sentiment regarding the strategic expansion.

Analysis

Illumina's definitive agreement to acquire SomaLogic for $350 million, plus up to $75 million in milestone payments, represents a significant strategic move to penetrate the high-growth proteomics market. This acquisition builds upon a 2021 co-development agreement, signaling a well-vetted technological and strategic fit. The deal is structured to bolster Illumina's multiomics roadmap by integrating SomaLogic’s aptamer-based proteomics technology with its own dominant next-generation sequencing (NGS) ecosystem, which is expected to create a new high-margin consumable revenue stream. Management projects the acquired business will achieve non-GAAP profitability by 2027 and align with Illumina's corporate non-GAAP operating margins by 2028, indicating a long-term value creation horizon. The market has reacted positively, with ILMN shares climbing 2.9% post-announcement and outperforming the industry by a wide margin over the past month with a 14% gain. This move is further supported by strong industry tailwinds, as the global proteomics market is projected to be worth $41.65 billion in 2025 and expand at a 14.9% CAGR through 2034. Despite a neutral Zacks Rank #3 (Hold), Illumina's fundamentals appear robust, evidenced by a 4.6% earnings yield that starkly contrasts with the industry's -27.7% average and a consistent history of beating earnings estimates by an average of 56.4% over the last four quarters.

Key Decisions for Investors

• Investors should view this acquisition as a long-term strategic positive that positions Illumina to capitalize on the rapidly expanding proteomics market, though financial contributions are not immediate.
• It is crucial to factor in the extended timeline, with the deal's closure not expected until the first half of 2026 and profitability from the SomaLogic unit projected for 2027, introducing execution and integration risk over the medium term.
• Monitor key milestones related to the integration of SomaLogic's technology with Illumina's NGS platforms and track early adoption rates of the combined offering post-launch to validate the synergy and revenue assumptions.
• Given the stock's recent 14% run-up, investors may consider the current Zacks 'Hold' rating as a signal to await a more opportune entry point or confirmation of integration progress before initiating new positions.